Mesoblast Ltd has released a press release.
FDA Grants Orphan Drug Designation for Revascor
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Mesoblast
- FDA Grants Rare Pediatric Disease Designation for Revascor
- Information For Retail Shareholders
- Mesoblast Completes Institutional Allocation
- Entitlement Offer and Placement Investor Presentation
- MSB Launches Entitlement Offer and Placement
Later from Mesoblast
- Half Year Financial Results Presentation
- MSB Q2 Financial Results and Operational Highlights
- FDA Supports Accelerated Approval Pathway for Heart Failure
- Mesoblast Completes Placement and Entitlement Offer
- FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast